Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Insulin: Biosynthesis, Chemistry, and Preparation01:25

Insulin: Biosynthesis, Chemistry, and Preparation

The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
Insulin Secretory Vesicles01:05

Insulin Secretory Vesicles

Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phosphoserine as an Alternative Energy Source for <i>E. coli</i> Cell-Free Protein Synthesis with Increased Yield and Prolonged Activity.

ACS synthetic biology·2026
Same author

Synergistic impact of 3D multicellular architecture and capillary-like flow on intestinal drug permeability.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences·2026
Same author

Editorial: Overcoming (in)visible barriers: gender, work and discrimination.

Frontiers in sociology·2026
Same author

Tolcapone-loaded nanostructured lipid carriers for improved oral delivery.

International journal of pharmaceutics·2026
Same author

Mitotic Machinery Dysregulation in Lung Cancer: Biological Roles, Therapeutic Targeting, and Combination Strategies.

Pharmaceutics·2026
Same author

Improved drug delivery across the blood-brain barrier through post-insertion functionalization of lipid nanocapsules with cannabidiol using click chemistry.

Colloids and surfaces. B, Biointerfaces·2026

Related Experiment Video

Updated: May 23, 2026

Solid Lipid Nanoparticles (SLNs) for Intracellular Targeting Applications
08:19

Solid Lipid Nanoparticles (SLNs) for Intracellular Targeting Applications

Published on: November 17, 2015

Chitosan-coated solid lipid nanoparticles for insulin delivery.

Pedro Fonte1, Fernanda Andrade, Francisca Araújo

  • 1Health Sciences Research Center, Instituto Superior de Ciências da Saúde, Norte, Rua Central de Gandra, Gandra, Portugal.

Methods in Enzymology
|March 28, 2012
PubMed
Summary

Researchers developed oral insulin delivery using solid lipid nanoparticles (SLN) coated with chitosan. This nanotechnology enhances intestinal absorption, offering a non-injectable alternative for diabetes management.

More Related Videos

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
09:34

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

Preparation and Characterization of SDF-1&#945;-Chitosan-Dextran Sulfate Nanoparticles
12:00

Preparation and Characterization of SDF-1α-Chitosan-Dextran Sulfate Nanoparticles

Published on: January 22, 2015

Related Experiment Videos

Last Updated: May 23, 2026

Solid Lipid Nanoparticles (SLNs) for Intracellular Targeting Applications
08:19

Solid Lipid Nanoparticles (SLNs) for Intracellular Targeting Applications

Published on: November 17, 2015

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
09:34

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

Preparation and Characterization of SDF-1&#945;-Chitosan-Dextran Sulfate Nanoparticles
12:00

Preparation and Characterization of SDF-1α-Chitosan-Dextran Sulfate Nanoparticles

Published on: January 22, 2015

Area of Science:

  • Biomaterials Science
  • Nanotechnology
  • Pharmaceutical Sciences

Background:

  • Traditional insulin delivery relies on injections, posing challenges for patient compliance and therapeutic efficacy.
  • Nanotechnology offers innovative solutions for drug delivery, particularly for labile biomolecules like insulin.
  • Oral administration of insulin is highly desirable but hindered by enzymatic degradation and poor absorption in the gastrointestinal tract.

Purpose of the Study:

  • To detail the preparation of solid lipid nanoparticles (SLN) for oral insulin delivery.
  • To characterize insulin-loaded SLN coated with chitosan for enhanced intestinal absorption.
  • To evaluate the in vitro and in vivo efficacy of this novel oral insulin delivery system.

Main Methods:

  • Preparation and characterization of solid lipid nanoparticles (SLN) encapsulating insulin.
  • Coating of SLN with mucoadhesive chitosan polymer.
  • Assessment of insulin integrity and encapsulation efficiency within SLN.
  • In vitro evaluation of intestinal permeability using Caco-2 cell models.
  • In vivo assessment of hypoglycemic effect in diabetic animal models.

Main Results:

  • Successfully prepared and characterized insulin-loaded SLN with chitosan coating.
  • Demonstrated preservation of insulin integrity post-encapsulation.
  • Showcased enhanced in vitro intestinal permeability of encapsulated insulin.
  • Confirmed significant hypoglycemic effect in diabetic animal models following oral administration.

Conclusions:

  • Chitosan-coated SLN provide a promising platform for oral insulin delivery.
  • This nanotechnology approach facilitates intestinal absorption and demonstrates therapeutic efficacy.
  • Offers a viable non-injectable alternative for insulin therapy in diabetes management.